The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to Paclitaxel

This is a "connection" page, showing publications Olufunmilayo Olopade has written about Paclitaxel.
Connection Strength

0.974
  1. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr; 15(2):e155-8.
    View in: PubMed
    Score: 0.432
  2. Breast Cancer Risk-Associated SNPs in the mTOR Promoter Form De Novo KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. Mol Cancer Res. 2019 11; 17(11):2244-2256.
    View in: PubMed
    Score: 0.152
  3. Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Mol Cancer Ther. 2019 05; 18(5):873-885.
    View in: PubMed
    Score: 0.147
  4. Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. Clin Breast Cancer. 2016 Jun; 16(3):e61-3.
    View in: PubMed
    Score: 0.119
  5. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
    View in: PubMed
    Score: 0.041
  6. HIF-2a promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. J Exp Clin Cancer Res. 2018 Oct 19; 37(1):256.
    View in: PubMed
    Score: 0.036
  7. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
    View in: PubMed
    Score: 0.031
  8. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.